431 related articles for article (PubMed ID: 27738913)
1. Strategies for the Discovery and Development of New Antibiotics from Natural Products: Three Case Studies.
Herrmann J; Lukežič T; Kling A; Baumann S; Hüttel S; Petković H; Müller R
Curr Top Microbiol Immunol; 2016; 398():339-363. PubMed ID: 27738913
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis.
Ganihigama DU; Sureram S; Sangher S; Hongmanee P; Aree T; Mahidol C; Ruchirawat S; Kittakoop P
Eur J Med Chem; 2015 Jan; 89():1-12. PubMed ID: 25462220
[TBL] [Abstract][Full Text] [Related]
4. Current perspectives in drug discovery against tuberculosis from natural products.
Nguta JM; Appiah-Opong R; Nyarko AK; Yeboah-Manu D; Addo PG
Int J Mycobacteriol; 2015 Sep; 4(3):165-83. PubMed ID: 27649863
[TBL] [Abstract][Full Text] [Related]
5. Natural antimicrobial peptides against Mycobacterium tuberculosis.
Abedinzadeh M; Gaeini M; Sardari S
J Antimicrob Chemother; 2015 May; 70(5):1285-9. PubMed ID: 25681127
[TBL] [Abstract][Full Text] [Related]
6. Target discovery focused approaches to overcome bottlenecks in the exploitation of antimycobacterial natural products.
Baptista R; Bhowmick S; Nash RJ; Baillie L; Mur LA
Future Med Chem; 2018 Apr; 10(7):811-822. PubMed ID: 29569936
[TBL] [Abstract][Full Text] [Related]
7. Opportunities and Challenges for Natural Products as Novel Antituberculosis Agents.
Farah SI; Abdelrahman AA; North EJ; Chauhan H
Assay Drug Dev Technol; 2016; 14(1):29-38. PubMed ID: 26565779
[TBL] [Abstract][Full Text] [Related]
8. The re-emerging role of microbial natural products in antibiotic discovery.
Genilloud O
Antonie Van Leeuwenhoek; 2014 Jul; 106(1):173-88. PubMed ID: 24923558
[TBL] [Abstract][Full Text] [Related]
9. Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins.
Kling A; Lukat P; Almeida DV; Bauer A; Fontaine E; Sordello S; Zaburannyi N; Herrmann J; Wenzel SC; König C; Ammerman NC; Barrio MB; Borchers K; Bordon-Pallier F; Brönstrup M; Courtemanche G; Gerlitz M; Geslin M; Hammann P; Heinz DW; Hoffmann H; Klieber S; Kohlmann M; Kurz M; Lair C; Matter H; Nuermberger E; Tyagi S; Fraisse L; Grosset JH; Lagrange S; Müller R
Science; 2015 Jun; 348(6239):1106-12. PubMed ID: 26045430
[TBL] [Abstract][Full Text] [Related]
10. Natural products as leads for tuberculosis drug development.
Salomon CE; Schmidt LE
Curr Top Med Chem; 2012; 12(7):735-65. PubMed ID: 22283816
[TBL] [Abstract][Full Text] [Related]
11. Biosynthetic and Synthetic Strategies for Assembling Capuramycin-Type Antituberculosis Antibiotics.
Biecker AL; Liu X; Thorson JS; Yang Z; Van Lanen SG
Molecules; 2019 Jan; 24(3):. PubMed ID: 30691073
[No Abstract] [Full Text] [Related]
12. New Griselimycins for Treatment of Tuberculosis.
Holzgrabe U
Chem Biol; 2015 Aug; 22(8):981-2. PubMed ID: 26295835
[TBL] [Abstract][Full Text] [Related]
13. Cystobactamids: myxobacterial topoisomerase inhibitors exhibiting potent antibacterial activity.
Baumann S; Herrmann J; Raju R; Steinmetz H; Mohr KI; Hüttel S; Harmrolfs K; Stadler M; Müller R
Angew Chem Int Ed Engl; 2014 Dec; 53(52):14605-9. PubMed ID: 25510965
[TBL] [Abstract][Full Text] [Related]
14. Discovery and Total Synthesis of Natural Cystobactamid Derivatives with Superior Activity against Gram-Negative Pathogens.
Hüttel S; Testolin G; Herrmann J; Planke T; Gille F; Moreno M; Stadler M; Brönstrup M; Kirschning A; Müller R
Angew Chem Int Ed Engl; 2017 Oct; 56(41):12760-12764. PubMed ID: 28730677
[TBL] [Abstract][Full Text] [Related]
15. Opportunities for natural products in 21
Wright GD
Nat Prod Rep; 2017 Jul; 34(7):694-701. PubMed ID: 28569300
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
Kigondu EM; Wasuna A; Warner DF; Chibale K
Bioorg Med Chem; 2014 Aug; 22(16):4453-61. PubMed ID: 24997576
[TBL] [Abstract][Full Text] [Related]
17. Construction of a new class of tetracycline lead structures with potent antibacterial activity through biosynthetic engineering.
Lešnik U; Lukežič T; Podgoršek A; Horvat J; Polak T; Šala M; Jenko B; Harmrolfs K; Ocampo-Sosa A; Martínez-Martínez L; Herron PR; Fujs Š; Kosec G; Hunter IS; Müller R; Petković H
Angew Chem Int Ed Engl; 2015 Mar; 54(13):3937-40. PubMed ID: 25650563
[TBL] [Abstract][Full Text] [Related]
18. Natural products in drug discovery: present status and perspectives.
Molinari G
Adv Exp Med Biol; 2009; 655():13-27. PubMed ID: 20047031
[TBL] [Abstract][Full Text] [Related]
19. Natural Products as a Source for Novel Antibiotics.
Moloney MG
Trends Pharmacol Sci; 2016 Aug; 37(8):689-701. PubMed ID: 27267698
[TBL] [Abstract][Full Text] [Related]
20. Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
Saxena S; Samala G; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
Bioorg Med Chem; 2015 Apr; 23(7):1402-12. PubMed ID: 25766629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
